MDT vs TNDM
MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions. TNDM: Tandem Diabetes Care provides advanced, consumer-focused automated insulin delivery systems designed to simplify diabetes management.
Side-by-side fundamentals
| Metric | MDT | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $94.63 | $16.52 | |
| Market cap | $121.0B | $1.1B | |
| P/E as of 2026-10-20 | 23.31 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2026 | 2.39 | n/a | |
| Net margin | +13.2% | -20.2% | MDT higher |
| Gross margin FY2025, SEC XBRL | n/a | +53.8% | |
| Operating margin | +17.8% | -18.5% | MDT higher |
| ROE | +9.7% | -131.9% | MDT higher |
| ROA | +5.2% | -23.2% | MDT higher |
| Debt / equity | 0.56 | 4.62 | MDT lower |
| Revenue growth (YoY) | +8.4% | +7.9% | MDT higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +8.2% | TNDM higher |
| Dividend yield as of 2026-09-03 | +3.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | MDT higher |
| Beta as of 2026-09-03 | 0.35 | 1.12 | |
| 1-year return as of 2026-10-20 close | -1.3% | +6.3% | TNDM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.